Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 11:00 ET | Source: Quell TX

Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025

Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and...
October 08, 2025 12:31 ET | Source: BCC Research LLC

Rheumatoid Arthritis Therapies Market to Hit $41.1B by 2030

Boston, Oct. 08, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Therapies for Rheumatoid Arthritis: Technologies and Global Markets” is projected to increase from $30.2...
September 24, 2025 14:37 ET | Source: SoCalBio

SoCalBio Investor & Partnership Conference to Feature Keynotes from SetPoint CEO Murthy Simhambhatla, PhD, and MedTech Industry Deal-Maker Ray Cohen

Keynotes for the 27th SoCalBio Conference will be delivered by Murthy Simhambhatla, PhD (SetPoint Medical) and Raymond W. Cohen (formerly Axonics).
September 02, 2025 02:00 ET | Source: Citryll

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 –...
August 25, 2025 10:14 ET | Source: Spherix Global Insights

US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights

EXTON, PA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in...
August 01, 2025 04:30 ET | Source: Research and Markets

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases

Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Tenosynovitis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
June 25, 2025 16:45 ET | Source: Vor Biopharma

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
April 10, 2025 09:12 ET | Source: Albatroz Therapeutics

Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May Reverse Disease Progression

Nature study uncovers insights about the progression of osteoarthritis (OA) and rheumatoid arthritis; demonstrates therapeutic approach targeting Calnexin.
November 14, 2024 16:30 ET | Source: Exagen Inc.

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
November 14, 2024 07:14 ET | Source: Research and Markets

Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel,...